ROCKVILLE, MD, March 8, 2005—EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced James S. Burns, President & CEO, will present a Corporate overview at the SG Cowen 25th Annual Health Care Conference being held March 14-17, 2005 in Boston. Mr. Burns is scheduled to present on Wednesday, March 16, 2005 from 9:40 a.m. to 10:20 a.m.

Mr. Burns’ live presentation will be web cast and can be accessed through the Company’s website at http://www.entremed.com and through SG Cowen’s website at http://www.sgcowen.com. An archive will be available on both websites for approximately 90 days.

About EntreMed

EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing therapeutic candidates for the treatment of cancer and inflammation. Panzem® (2-Methoxyestradiol or 2ME2), the Company’s lead drug candidate, is currently in clinical trials for advanced cancer, as well as in preclinical development for indications outside of oncology. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell cycle regulation and inflammation—processes vital to the treatment of cancer and other diseases. The Company’s expertise has also led to the discovery of new molecules, including analogs of 2ME2, peptides of tissue factor pathway inhibitor (TFPI), and inhibitors of fibroblast growth factor-2 (FGF-2) and proteinase activated receptor-2 (PAR-2). EntreMed is developing these potential drug candidates for either in-house advancement or external partnering. Additional information about EntreMed is available on the Company’s website at http://www.entremed.com and in various filings with the Securities and Exchange Commission.